릴리와 CSL, 클라자키주맙 항체 개발 파트너십 체결
Thursday, March 12, 2026
2 min read
정규 소스Australia
Summary Only30%
변경 사항
Eli Lilly and CSL have partnered to jointly develop clazakizumab, an anti-interleukin-6 monoclonal antibody, through a strategic licensing agreement.
Source Report
CSL and Eli Lilly have entered into a strategic licensing agreement for the development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody.
Sigvera Intelligence
Industry Context
Healthtech & Biotech
Where this signal fits in the broader landscape.
Partnership
Company Activity전체 보기
No recent signals tracked yet.
Source Verification
Verified from official source
Publisher—
게시일Mar 12, 2026
소스 분류Verified Canonical
시그널 타임라인
최초 보도Mar 12, 2026
인덱싱Mar 12, 2026
게시Mar 12, 2026
https://www.pharmtech.com/view/lilly-and-csl-partner-on-clazakizumab-antibody-development
Read Full Source신뢰도:80%
Get cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
로그인